Yesterday Boehringer Ingelheim (BI) formally acquired Amgen's biopharmaceutical development and manufacturing facility in Fremont, California (USA). The facility currently employs more than 300 and consists of more than 200,000 square feet for laboratories, manufacturing and process development.
"Presence in Fremont, CA aligns with our growth strategy," said Simon Sturge, Corporate Senior Vice President Biopharmaceuticals, Boehringer Ingelheim GmbH. "The state-of-the-art contract manufacturing facility in the U.S. Bay Area biotechnology cluster will give Boehringer Ingelheim a greater opportunity to serve current and future customers. In addition the technological expertise present at Fremont will complement our goal to further increase Boehringer Ingelheim's world leading position in the process development and manufacture of biopharmaceuticals."
Boehringer Ingelheim Finalizes Acquisition Of AMGEN's Fremont Facility In The USA.
The Fremont site complements the existing capabilities and technology found across the existing BI biopharma network located in Biberach/Germany and Vienna/Austria. BI has been a contract manufacturer for Amgen for ten years and will continue to support Amgen's delivery of safe and effective medicines to patients around the world.
The BI contract manufacturing portfolio includes sixteen licensed biopharmaceuticals manufactured in globally licensed multi-product facilities, a growing pipeline of New Biological Entities (NBEs), and a growth strategy in the Contract Manufacturing Business (CMB). Boehringer Ingelheim's objective is to remain a leader in Contract Manufacturing as an industry benchmark for operational excellence.
Posted by Bruce Lehr March 27th 2011.